ECOR earnings

First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million Company to host a conference call and webcast today, May 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2026. The Company reported record quarterly revenue of $9.6 million, an increase of approximately 43% year-over-year, driven by continued growth in U.S. prescription sales in

Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a

Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue

Net sales of $7.4 million increased 20% vs. Q2'2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025  Company to host a conference call and webcast today, August 6, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the three and six months ended June 30, 2025. Recent Highlights Record revenue for Q2'2025 of $7.4 million, a 20% increase over Q2'2024Year-to-Date revenue of $14.1 million, a

First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine Company and wellness company, today announced fourth quarter and full year 2024 financial results. Recent Highlights Reported record full year of 2024 revenue of $25.2 m

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Details Date: Wednesday, March 12, 2025Time: 5:30 PM EDTRegistration: Click here to register to receive login credentials and dial-in details. About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine a

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales  Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights Eighth consecutive record quarterly revenue of $6.6 million, an increase of 45% over third quarter 2023Year to date, revenue of $18.1 million; an increase of 67% over the first nine months of 2023Sales of Rx gammaCore™ and Truvaga™ before variable TAC-STIM™ sa

ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2024, after the close of the market on Wednesday, November 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, November 13, 4:30 PM ESTDial-In:  877-407-8835 / +1 201-689-8779Conference ID: 13744121Webcast:  electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improv

ROCKAWAY, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2024, after the close of the market on Wednesday, August 7, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, August 7, 4:30 PM EDTDial-In: 877-407-8835 / +1 201-689-8779Conference ID: 13744119Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal

Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2024 financial results. Recent Highlights Record revenue of $5.4 million, an increase of 96% over first quarter 2023Launched our direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus™ First Quarter 2024 Financial Results For the quarter ended March 31, 2024, electroCore reported net sales of $5.4 million c

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDTDomestic: 877-407-8835International: located hereConference ID: 13744118Webcast:  electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, March 13, 4:30 PM ESTDomestic: 877-407-8835International: located hereConference ID: 13744117Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicat

ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, November 8, 2023, 4:30 PM ESTDomestic: 877-407-8835International: located hereConference ID: 13739201Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicat

ROCKAWAY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August 9, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, August 9, 2023, 4:30 PM EDTDomestic: 877-407-8835International: +1 201-689-8779Conference ID: 13739200Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to

Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023, at 4:30 PM EDT ROCKAWAY, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2023 financial results and provided an operational update.  First Quarter 2023 and Recent Highlights Record revenue of $2.8 million, an increase of approximately 46% over first quarter 2022The Air Force Research Laboratories reported human performance data from its study suggesting that gammaCore™ non-invasive vagus nerve stimulatio

ROCKAWAY, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 3, 2023, 4:30 PM EDTDomestic: 877-269-7756International: 201-689-7817Conference ID: 13738144Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health thr

Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) (the "Company"), a commercial-stage bioelectronic medicine and wellness company, today announced fourth quarter and full year 2022 financial results and provided an operational update. Fourth Quarter 2022 and Recent Highlights Reported record full year 2022 net sales of $8.6 million, representing an increase of 58% over $5.5 million for full year 2021Fourth quarter net sales of $2.6 million, an increase of 72% over $1.5 million f

ROCKAWAY, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2022, after the close of the market on Wednesday, March 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.Wednesday, March 8, 2023, 4:30 PM ESTDomestic: 877-269-7756International: 201-689-7817Conference ID: 13736452Webcast: electroCore Earnings WebcastAbout electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicat

Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today, November 3, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced third quarter 2022 financial results and provided an operational update.  Third Quarter 2022 and Recent Highlights Posted revenue of approximately $2.0 million, representing an increase of approximately 33% over third quarter 2021Net cash used in operating activities was $4.6 million during the third quarter 2022 leaving approximately $21.9 million of cash and cash equivalents at September 30, 2022Str

ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the third quarter ended September 30, 2022, after the close of the market on Thursday, November 3, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Thursday, November 3, 2022, 4:30 PM EDT Domestic: 877-269-7756 International: 201-689-7817 Conference ID: 13733010 Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient

ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (NASDAQ:ECOR) (the "Company"), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal year 2022 annual meeting of stockholders (the "2022 Annual Meeting") on Friday, December 2, 2022. Current plans are for the meeting to be held virtually by means of remote communication. The Company will publish additional details regarding the exact time, record date and matters to be voted on at the 2022 Annual Meeting in the Company's proxy statement for the 2022 Annual Meeting. The Company anticipates sending proxy materials for the annual meeting to stockholders in October 2022. Submissio

Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and webcast today, August 4, 2022 at 4:30 pm EDT ROCKAWAY, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced second quarter 2022 financial results and provided an operational update. Second Quarter 2022 and Recent Highlights  Posted revenue of $2.2 million, representing an increase of approximately 70% over second quarter 2021 and 14% sequentially;Net cash used in operating activities was $3.2 million during the second quarter 2022 leaving approximately $26.

ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the second quarter ended June 30, 2022, after the close of the market on Thursday, August 4, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Thursday, August 4, 2022, 4:30 PM EDTDomestic: 877-269-7756International: 201-689-7817Conference ID: 13731362Webcast: electroCore Earnings WebcastAbout electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes thr

First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ROCKAWAY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced first quarter 2022 financial results and provided an operational update.   First Quarter 2022 and Recent Highlights Posted revenue of $1.9 million, representing an increase of approximately 58% over first quarter 2021 and 27% sequentially;Net cash used in operating activities was $4.8 million during the first quarter 2022 leaving approximately $29.9 mil

ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022, after the close of the market on Thursday, May 5, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.Thursday, May 5, 2022, 4:30 PM EDTDomestic: 877-269-7756International: 201-689-7817Conference ID: 13728177 Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through i

Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalents of $34.7 million Company to host conference call and webcast today, March 10, 2022, at 4:30 PM EST ROCKAWAY, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter and full year 2021 financial results and provided an operational update. Fourth Quarter 2021 and Recent Highlights Reported full year 2021 net sales of approximately $5.5 million, representing an increase of 56% over $3.5 million for full year 2020;Fourth quarter net sales of ap

ROCKAWAY, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2021, after the close of the market on Thursday, March 10, 2022. Management will host a conference call and webcast at 4:30 PM Eastern Standard Time to discuss the financial results and answer questions. Thursday, March 10, 2022, 4:30 PM Eastern Standard TimeDomestic: 877-269-7756International: 201-689-7817Conference ID: 13726544Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine c

ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions. Thursday, November 4, 2021, 4:30pm Eastern TimeDomestic: 877-269-7756International: 201-689-7817Conference ID: 13722407Webcast: electroCore 3Q21 Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving

ROCKAWAY, NJ, July 22, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions. Thursday, August 5, 2021, 4:30pm Eastern TimeDomestic: 888-506-0062International: 973-528-0011Conference ID: 748491Webcast: electroCore 2Q21 Business Update WebcastAbout electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving pati